It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al. There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant […]
It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al. There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant […]
I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates. My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline […]
I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates. My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline […]